News
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts.
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...
The insolvent genetic analysis company 23andme is taken over by a pharmaceutical company that wants to continue the business ...
23andMe's stock, which once traded for more than $300 a share, fell to 79 cents before the start of trade Monday. In January, 23andMe reported a third-quarter net loss of $26.8 million on ...
Claims are now open for nearly 7 million people who were affected by 23andMe's data breach in 2023, with the beleaguered DNA-tracking company agreeing to pay a settlement worth $30 million.
23andMe has found a buyer in biotech company Regeneron Pharmaceuticals. Its business floundered after a data hack, lawsuit, and tumbling stock prices. For those concerned about their dataset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback